| Business Summary | | Progen
Industries
Limited
is
an
Australian
biotechnology
company
that
provides
biopharmaceutical
research,
contract
services,
life
science
research
products,
and
bulk
proteins.
Involved
in
pharmaceutical
research
and
development,
Progen
recently
commenced
its
second
Phase
I
clinical
trial
with
its
lead
compound
(PI-88)
for
treatment
of
solid
tumors.
Contract
Services
is
an
established
Strategic
Business
Unit
of
Progen
that
is
recognized
as
an
international
provider
of
specialized
bioprocess
services,
including
cGMP
manufacture
of
biopharmaceuticals
for
clinical
trials.
Progen
offers
a
wide
range
of
innovative
products
to
meet
clients'
Life
Science
research
needs.
These
include
Progen,
CLONTECH,
Pierce
Chemical
Co,
MBI
Fermentas,
Labnet,
HyClone,
and
MoBiTec.
Progen
is
a
manufacturer
of
proteins,
derived
from
both
animal
and
fermentation
sources,
in
bulk
quantities. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Progen
Industries
Limited
is
engaged
in
the
design
and
development
of
unique
carbohydrate
pharmaceuticals
to
treat
a
variety
of
disease
conditions,
including
cancer,
cardiovascular
disease
and
inflammations.
For
the
fiscal
year
ended
6/30/00,
revenues
rose
73%
to
$1.5
million.
Net
loss
fell
7%
to
$4.5
million.
Revenues
reflect
an
increase
in
life
sciences
sales.
Net
loss
were
partially
offset
by
higher
diminution
of
investments
and
increased
S/G/A
expenses. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Stephen Chang | Chairman | Lewis Lee | Managing
Director | John Grew | VP-Operations | Megan Fisher, Ph.D. | VP
of Sales and Marketing | Kaye Roberts | VP
- Quality Assurance |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|